Methyltestosterone


ToxCast endpoints for intended target type: RNA
Assay NameTissueOrganismTarget Gene IDTarget HGNC SymbolResponseAC50 Value
LTEA_HepaRG_ABCB1LiverHuman5243ABCB1Inhibitory0.71 μM
LTEA_HepaRG_ABCB11LiverHuman8647ABCB11Activatory0.65 μM
LTEA_HepaRG_CYP2C19LiverHuman1557CYP2C19Inhibitory0.21 μM
LTEA_HepaRG_CYP7A1LiverHuman1581CYP7A1Activatory1.9 μM
LTEA_HepaRG_MMP3LiverHuman4314MMP3Activatory0.95 μM
LTEA_HepaRG_PEG10LiverHuman23089PEG10Activatory2.07 μM
LTEA_HepaRG_THRSPLiverHuman7069THRSPActivatory0.81 μM

ToxCast endpoints for intended target type: Protein
Assay NameTissueOrganismTarget Gene IDTarget HGNC SymbolResponseAC50 Value
CCTE_Deisenroth_AIME_384WELL_LUC_ActiveMammary gland/breastHuman2099ESR1Gain1.8 μM
CCTE_Deisenroth_AIME_384WELL_LUC_InactiveMammary gland/breastHuman2099ESR1Gain1.62 μM
CCTE_Deisenroth_AIME_384WELL_LUC_ShiftMammary gland/breastHuman2099ESR1Inhibitory0.99 μM
ATG_ERE_CISLiverHuman2099ESR1Inhibitory0.01 μM
ATG_AR_TRANSLiverHuman367ARGain0.01 μM
ATG_ERa_TRANSLiverHuman2099ESR1Gain0.01 μM
ATG_ERE_CISLiverHuman2099ESR1Activatory0.05 μM
ATG_AR_TRANSLiverHuman367ARGain0.06 μM
ATG_ERa_TRANSLiverHuman2099ESR1Gain0.06 μM
ATG_AP_1_CISLiverHuman2353|3725FOS|JUNInhibitory113.98 μM
ATG_MRE_CISLiverHuman4520MTF1Inhibitory129.09 μM
ATG_PXRE_CISLiverHuman8856NR1I2Inhibitory8.23 μM
ATG_AR_TRANSLiverHuman367ARGain0.03 μM
NVS_ADME_rCYP2A2Rat24895Cyp2a2Loss5.45 μM
NVS_ADME_rCYP2C11Rat29277Cyp2c11Loss2.16 μM
NVS_NR_hGRHuman2908NR3C1Loss0.31 μM
NVS_NR_rARProstateRat24208ArLoss0.06 μM
NVS_ADME_rCYP2C11Rat29277Cyp2c11Loss2.26 μM
NVS_NR_hERHuman2099ESR1Loss7.88 μM
NVS_NR_hGRHuman2908NR3C1Loss0.2 μM
NVS_NR_hPXRHuman8856NR1I2Loss8.26 μM
NVS_NR_rARProstateRat24208ArLoss0.05 μM
NVS_ADME_rCYP2C11Rat29277Cyp2c11Loss3.81 μM
NVS_NR_hERHuman2099ESR1Loss8.29 μM
NVS_NR_hGRHuman2908NR3C1Loss0.4 μM
NVS_NR_rARProstateRat24208ArLoss0.12 μM
ATG_DR4_LXR_CISLiverHuman7376|10062NR1H2|NR1H3Inhibitory162.91 μM
ATG_ERE_CISLiverHuman2099ESR1Activatory0.01 μM
ATG_MRE_CISLiverHuman4520MTF1Activatory131.85 μM
NVS_IC_rNaCh_site2BrainRat81574Scn1aLoss2.11 μM
NVS_NR_hARHuman367ARLoss0.0 μM
NVS_NR_hPRHuman5241PGRLoss0.18 μM
NVS_NR_rMRBrainRat25672Nr3c2Loss0.07 μM
NVS_NR_hERHuman2099ESR1Loss8.57 μM
NVS_NR_rARProstateRat24208ArLoss0.03 μM
NVS_OR_gSIGMA_NonSelectiveBrainGuinea pig100135589Sigmar1Loss4.45 μM
ATG_hAR_XSP1LiverHuman367ARGain0.0 μM
ATG_hERa_XSP1LiverHuman2099ESR1Gain0.0 μM
ATG_hERb_XSP1LiverHuman2100ESR2Gain0.01 μM
ATG_hERb_XSP2LiverHuman2100ESR2Gain0.01 μM
ATG_hAR_XSP2LiverHuman367ARGain0.0 μM
ATG_hERa_XSP2LiverHuman2099ESR1Gain0.0 μM
TOX21_AR_BLA_Agonist_ratioKidneyHuman367ARGain0.01 μM
TOX21_AR_LUC_MDAKB2_AgonistBreastHuman367ARGain0.0 μM
TOX21_ERa_BLA_Agonist_ratioKidneyHuman2099ESR1Gain7.84 μM
TOX21_ERa_LUC_VM7_AgonistBreastHuman2099ESR1Gain0.2 μM
TOX21_GR_BLA_Antagonist_ratioCervixHuman2908NR3C1Loss6.0 μM
TOX21_ERa_BLA_Agonist_ratioKidneyHuman2099ESR1Gain7.33 μM
TOX21_ERa_LUC_VM7_AgonistBreastHuman2099ESR1Gain0.19 μM
TOX21_GR_BLA_Antagonist_ratioCervixHuman2908NR3C1Loss4.65 μM
TOX21_AR_LUC_MDAKB2_Agonist_3uM_NilutamideBreastHuman367ARGain0.03 μM
TOX21_ERb_BLA_Agonist_ratioKidneyHuman2100ESR2Gain4.93 μM
TOX21_PR_BLA_Agonist_ratioKidneyHuman5241PGRGain0.81 μM
TOX21_PR_BLA_Antagonist_ratioKidneyHuman5241PGRLoss0.05 μM
TOX21_AR_BLA_Agonist_ratioKidneyHuman367ARGain0.0 μM
TOX21_ERa_BLA_Agonist_ratioKidneyHuman2099ESR1Gain5.34 μM
TOX21_ERa_LUC_VM7_AgonistBreastHuman2099ESR1Gain0.13 μM
TOX21_GR_BLA_Antagonist_ratioCervixHuman2908NR3C1Loss3.91 μM
TOX21_ERb_BLA_Agonist_ratioKidneyHuman2100ESR2Gain4.16 μM
TOX21_PR_BLA_Agonist_ratioKidneyHuman5241PGRGain0.76 μM
TOX21_PR_BLA_Followup_Agonist_ratioKidneyHuman5241PGRGain2.04 μM
TOX21_PR_LUC_Followup_AgonistKidneyHuman5241PGRGain0.13 μM

ToxCast endpoints for intended target type: Molecular messenger
Assay NameTissueOrganismTarget Gene IDTarget HGNC SymbolResponseAC50 Value
CEETOX_H295R_OHPREGAdrenal glandHuman5241PGRInhibitory4.79 μM
CEETOX_H295R_OHPROGAdrenal glandHuman5241PGRInhibitory0.81 μM
CEETOX_H295R_CORTISOLAdrenal glandHuman2908|4306NR3C1|NR3C2Inhibitory6.29 μM
CEETOX_H295R_ESTRADIOLAdrenal glandHuman2099|2100ESR1|ESR2Activatory5.44 μM
CEETOX_H295R_ESTRONEAdrenal glandHuman2099|2100ESR1|ESR2Inhibitory7.03 μM

ToxCast endpoints for intended target type: Pathway
Assay NameTissueOrganismTarget Gene IDTarget HGNC SymbolResponseAC50 Value
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_AgonistBoneHuman367ARGain0.0 μM
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_AgonistBoneHuman367ARGain0.0 μM
ACEA_ER_80hrBreastHuman2099ESR1Gain1.66 μM
ACEA_ER_80hrBreastHuman2099ESR1Gain0.06 μM
ACEA_ER_80hrBreastHuman2099ESR1Gain0.05 μM
OT_AR_ARELUC_AG_1440OvaryChinese hamster367ARGain0.0 μM
OT_AR_ARSRC1_0480KidneyHuman367|6714AR|SRCGain0.13 μM
OT_AR_ARSRC1_0960KidneyHuman367|6714AR|SRCGain0.04 μM
OT_AR_ARELUC_AG_1440OvaryChinese hamster367ARGain0.01 μM
OT_AR_ARSRC1_0480KidneyHuman367|6714AR|SRCGain0.03 μM
OT_AR_ARSRC1_0960KidneyHuman367|6714AR|SRCGain0.03 μM
OT_AR_ARSRC1_0960KidneyHuman367|6714AR|SRCGain0.06 μM
OT_AR_ARSRC1_0480KidneyHuman367|6714AR|SRCGain0.0 μM
OT_AR_ARSRC1_0960KidneyHuman367|6714AR|SRCGain0.0 μM
ACEA_AR_agonist_80hrProstateHuman367ARGain0.0 μM
TOX21_H2AX_HTRF_CHO_Agonist_ratioOvaryChinese hamster3014H2AXGain110.23 μM

No ToxCast endpoints for intended target type: Cellular

No ToxCast endpoints for intended target type: Hormone
DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.